Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model. (2018). Farmeconomia. Health Economics and Therapeutic Pathways, 19(1). https://doi.org/10.7175/fe.v19i1.1328